LatviaTuberculosis profile
Population  2014 2 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.054 (0.053–0.055) 2.7 (2.7–2.8)
Mortality (HIV+TB only) 0.019 (0.014–0.024) 0.96 (0.72–1.2)
Prevalence  (includes HIV+TB) 1.1 (0.55–1.9) 57 (28–96)
Incidence  (includes HIV+TB) 0.98 (0.91–1) 49 (46–53)
Incidence (HIV+TB only) 0.21 (0.19–0.24) 11 (9.4–12)
         
Case detection, all forms (%) 76 (71–81)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 8.2 (5.8–11) 30 (21–40)
MDR-TB cases among notified pulmonary
TB cases
48 (34–64) 37 (26–49)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 487   91
Pulmonary, clinically diagnosed 97   9
Extrapulmonary 53   1
       
Total new and relapse 738    
Previously treated, excluding relapses 23    
Total cases notified 761    
Among 738 new and relapse cases:
41 (6%) cases aged under 15 years; male:female ratio: 2.5
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 483 (99%) 107 (86%) 590
Laboratory-confirmed RR-/MDR-TB cases     71
Patients started on MDR-TB treatment ***     70
TB/HIV 2014 Number (%)
TB patients with known HIV status 488 (64)
HIV-positive TB patients 95 (19)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 48 (51)
HIV-positive TB patients on antiretroviral therapy (ART) 55 (58)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (83) 804
Previously treated cases, excluding relapse, registered in 2013 (81) 21
HIV-positive TB cases, all types, registered in 2013 (67) 79
RR-/MDR-TB cases started on second-line treatment in 2012 (63) 90
XDR-TB cases started on second-line treatment in 2012 (53) 17
Laboratories 2014  
Smear (per 100 000 population) 0.6
Culture (per 5 million population) 12.6
Drug susceptibility testing (per 5 million population) 2.5
Sites performing Xpert MTB/RIF 2
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 1.6
% Funded domestically 100%
% Funded internationally  
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-25 Data: www.who.int/tb/data